Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$137.77 USD

137.77
2,767,283

+1.25 (0.92%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $138.00 +0.23 (0.17%) 7:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Zacks Equity Research

Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System

by Zacks Equity Research

Stryker (SYK) announces the launch of LIFEPAK 35 monitor/defibrillator, which is likely to aid emergency responders to reduce cognitive load during demanding situations by improving workflow.

Zacks Equity Research

DexCom (DXCM) Declines on Potential Competition for Stelo (revised)

by Zacks Equity Research

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

Zacks Equity Research

Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market

by Zacks Equity Research

Stryker (SYK) announces the signing of the definitive agreement to acquire a privately held company, Artelon, to strengthen its foothold in the soft tissue fixation market.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Zacks Equity Research

HealthEquity (HQY) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2025.

Zacks Equity Research

Inari's (NARI) Expanding Product Portfolio Offsets Competition

by Zacks Equity Research

Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.

Zacks Equity Research

DexCom (DXCM) Declines on Potential Competition for Stelo

by Zacks Equity Research

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment

by Zacks Equity Research

ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.

Zacks Equity Research

Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M

by Zacks Equity Research

Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.

Zacks Equity Research

Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both segments.

Zacks Equity Research

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Zacks Equity Research

Stryker (SYK) to Launch Gamma4 Hip Fracture System in Europe

by Zacks Equity Research

Stryker (SYK) announces plan to launch its Gamma4 Hip Fracture Nailing System in Europe. It completes initial surgeries successfully.

Zacks Equity Research

Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now

by Zacks Equity Research

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

Zacks Equity Research

Strength in HSA Likely to Aid HealthEquity's (HQY) Q1 Earnings

by Zacks Equity Research

Continued strength in HSA, aided by transfers of HSA Assets from BenefitWallet, is likely to have boosted HealthEquity's (HQY) top line in the fiscal first quarter.

Zacks Equity Research

Stryker (SYK) Issues Safety Notice for Its Total Knee System

by Zacks Equity Research

Stryker (SYK) issues urgent field safety notice for the Mako Total Knee systems, the application software of which generated software error codes. The company also shares risk mitigation steps.

Zacks Equity Research

Reasons to Retain PacBio (PACB) Stock in Your Portfolio

by Zacks Equity Research

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Zacks Equity Research

Reasons to Retain Baxter International (BAX) in Your Portfolio Now

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Zacks Equity Research

Intuitive Surgical (ISRG) Stock Gains 20% YTD: Here's Why

by Zacks Equity Research

Intuitive Surgical (ISRG) shares gain on the back of growth in the da Vinci treatment volume and raised procedure prices.

Zacks Equity Research

Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. Gross margins improve. However, the rising cost of products is a concern.

Zacks Equity Research

ResMed (RMD) Up 16.3% Since Last Earnings: Will it Continue?

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) led by strong growth in the U.S. mask and accessories business and its cloud-connected platforms.

Zacks Equity Research

Inari Medical (NARI) Sues Truvic on Patent Infringement

by Zacks Equity Research

Inari Medical (NARI) files a patent infringement lawsuit against Imperative Care and its subsidiary Truvic over intentionally copying and overlapping the designs of Inari Medical's products.

Zacks Equity Research

Integer Holdings (ITGR) Gains 23.6% YTD: What's Driving the Stock?

by Zacks Equity Research

Integer Holdings (ITGR) shares soar on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.

Zacks Equity Research

Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias

by Zacks Equity Research

Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.